Advertisement

Topics

Mirabegron, A Selective β3-Adrenoceptor Agonist Causes an Improvement in Erectile Dysfunction in Diabetic Rats.

08:00 EDT 12th April 2019 | BioPortfolio

Summary of "Mirabegron, A Selective β3-Adrenoceptor Agonist Causes an Improvement in Erectile Dysfunction in Diabetic Rats."

To investigate the possible beneficial effect of mirabegron [a selective β-adrenoceptor (AR) agonist] treatment on erectile dysfunction (ED) in streptozotocin-induced diabetic rats.

Affiliation

Journal Details

This article was published in the following journal.

Name: Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
ISSN: 1439-3646
Pages:

Links

DeepDyve research library

PubMed Articles [10401 Associated PubMed Articles listed on BioPortfolio]

Validation of LC-MS/MS methods for the determination of mirabegron and eight metabolites in human plasma in a paediatric population.

Mirabegron is the first registered β3-adrenoceptor agonist for treatment of overactive bladder as an alternative to antimuscarinics. Previously four liquid chromatography-tandem mass spectrometry ass...

Assessment of the erectile function and patients' perception of improvement in Spanish patients with erectile dysfunction.

This study has been carried out to assess the hardness of erection and the perception of improvement in erectile function with the treatments received during the last month.

Penile rehabilitation for postprostatectomy erectile dysfunction.

Despite efforts to preserve the neurovascular bundles with nerve-sparing surgery, erectile dysfunction remains common following radical prostatectomy. Postoperative penile rehabilitation seeks to rest...

Association Between Erectile Dysfunction and Carotid Subclinical Atherosclerosis in HIV-Infected Patients.

Erectile dysfunction (ED) is frecuent in HIV infected patients and it can be associated with atherosclerosis and cardiovascular events. So, the objetive was to evaluate whether the presence of moderat...

Clinical Profile of Young Patients with Erectile Dysfunction: Preliminary Findings of a Real-life Cross-sectional Study.

Erectile dysfunction (ED) is an increasingly common complaint among men aged

Clinical Trials [5727 Associated Clinical Trials listed on BioPortfolio]

Mirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized Study

To study the impact of mirabegron, a B3-adrenoceptor agonist, in the treatment of ED in patients with LUTS secondary to BPH and concomitant ED.

Mirabegron For Erectile Dysfunction

The only class of oral erectile dysfunction (ED) medication on the market are the phosphodiesterase Type 5 inhibitors (PDE5i). This pilot study is being done to evaluate the effect of Mira...

A Study of DA-8159 in Subjects With Erectile Dysfunction

The purpose of this study will be to evaluate the clinical efficacy and safety of DA-8159, an orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment ...

Treatment of Erectile Dysfunction I

Randomized, placebo-controlled, double-blind, parallel design, Phase 3 study to evaluate the safety and efficacy of udenafil, an orally administered, potent and selective inhibitor of PDE-...

Treatment of Erectile Dysfunction II

Randomized, placebo-controlled, double-blind, parallel design, Phase 3 study to evaluate the safety and efficacy of udenafil, an orally administered, potent and selective inhibitor of PDE-...

Medical and Biotech [MESH] Definitions

The inability in the male to have a PENILE ERECTION due to psychological or organ dysfunction.

Inability to achieve and maintain an erection (ERECTILE DYSFUNCTION) due to defects in the arterial blood flow to the PENIS, defect in venous occlusive function allowing blood drainage (leakage) from the erectile tissue (corpus cavernosum penis), or both.

Surgical insertion of cylindric hydraulic devices for the treatment of organic ERECTILE DYSFUNCTION.

Drugs used in the treatment of urogenital conditions and diseases such as URINARY INCONTINENCE; PROSTATIC HYPERPLASIA; and ERECTILE DYSFUNCTION.

A carboline derivative and PHOSPHODIESTERASE 5 INHIBITOR that is used primarily to treat ERECTILE DYSFUNCTION; BENIGN PROSTATIC HYPERPLASIA and PRIMARY PULMONARY HYPERTENSION.

Advertisement
Quick Search
Advertisement
Advertisement

 


DeepDyve research library

Relevant Topics

Diabetes
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...

Erectile Dysfunction
Erectile dysfunction (ED or impotence) is the inability to get and maintain an erection that is sufficient for satisfactory sexual intercourse, and affects half of all men between the ages of 40 to 70. The causes of ED can be both physical and psycholo...


Searches Linking to this Article